Dr. Navid Nami, DO

Dr. Nami practices at Island Dermatology, Inc in Glendora, California.

Dr. Nami's NPI, 1710936646, was assigned on May 8, 2006. Dr. Nami graduated from WesternU College of Osteopathic Medicine of the Pacific in 1999. Dr. Nami holds California license 20A9494.

Dr. Nami's primary practice is Island Dermatology, Inc, at 210 S Grand Ave, Glendora, CA 91741 in Los Angeles County. The practice phone is (949) 720-1170.

Dr. Nami's primary practice is Island Dermatology, Inc in Glendora, California. Dr. Nami is also affiliated with Hoag Hospital Newport Beach. The medical group on file is Island Dermatology. Dmand AI also links Dr. Nami to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Nami practices, 2 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Nami's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Nami is board certified in dermatology by the American Osteopathic College of Dermatology. Dr. Nami is licensed in California.

Dmand AI lists acne, acute skin infection, benign or precancerous skin growths, cold sores or genital herpes, contact dermatitis, hives, itchy rashes and psoriasis among the conditions Dr. Nami treats.

CMS data shows 3,331 Medicare services from Dr. Nami across 11 procedure codes in 2024, for 498 Medicare patients. Medicare paid $146,753 for them. Every service was in an office.

CMS counts 498 Medicare patients who saw Dr. Nami in 2024. The largest group is 65 to 74, with 237 patients. 75% of them have high cholesterol, and 64% have high blood pressure. 17% are also on Medicaid. Their average risk score is 1.07, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Nami's median patient age at 62, with 58% women.

In 2024, Dr. Nami wrote 938 Medicare Part D claims for 406 patients. 85% of them were for generic drugs. CMS names the drug for 826 of them, across 15 drugs with 11 or more claims each, at $559,105 in total drug cost. In 2023, CMS named 2,204 claims across 22 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Nami for performance year 2024, reported as part of a group. Dr. Nami accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 868 procedures of removal of skin lesions by Dr. Nami, more than 92% of the clinicians it reports for that procedure.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Removal or shaving of skin growth: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 8 papers to Dr. Nami, published from 2019 to 2024. The most frequent topics are Administration, Topical. Dr. Nami has published most often in Cutis. Dr. Nami's most frequent co-authors are Paul K. Shitabata, MD, Leela Athalye, DO and Leila Ettefagh, MD.

Dmand AI links Dr. Nami to 7 clinical trials. Conditions studied include Psoriasis, Skin Diseases, Papulosquamous and Eczema. Eli Lilly and Company sponsors the most, 6. Open Payments lists research payments to Dr. Nami that name 3 trials.

CMS Open Payments shows 713 general payments to Dr. Nami from 34 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 80% of the total. Amgen Inc. paid the most, $138,734. It also lists 9 research payments totaling $73,551 from 2018 to 2023, naming 3 clinical trials.

Dmand AI lists 1 award for Dr. Nami.

Dr. Nami graduated from WesternU College of Osteopathic Medicine of the Pacific in 1999. Dr. Nami is a member of AOA.

Dr. Nami is in network with 16 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. Medicare plans come from the most carriers, 11. Check the plan with the practice before a visit.